Stockscreener 앱 받기
1.839
3.09%
0.059
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
ACRVAcrivon Therapeutics Inc Options - Finviz
ACRIVON THERAPEUTICS INC (ACRV) Stock Price & Overview - ChartMill
Price to book forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Price to sales forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Acrivon Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRV) - TradingView
ACRV Forecast — Price Target — Prediction for 2027 - TradingView
Acrivon Therapeutics (ACRV) Slips 2.47% in Low-Volume Trade, Testing Key Support at $1.5Sector ETF Flow - dars.gov.et
Form 4 Acrivon Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Director-linked RA Capital funds receive 20,275 Acrivon (ACRV) stock options at $1.52 - Stock Titan
Acrivon (NASDAQ: ACRV) director granted 20,275 stock options at $1.52 - Stock Titan
Acrivon Therapeutics (ACRV) director Sharon Shacham awarded 20,275 stock options - Stock Titan
Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 strike - Stock Titan
Acrivon Therapeutics (ACRV) director granted options on 20,275 shares - Stock Titan
Acrivon Therapeutics (ACRV) director awarded 20,275-share option for RA Capital funds - Stock Titan
Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 - Stock Titan
Acrivon Shareholders Approve Expanded Equity Plan and Directors - The Globe and Mail
Acrivon Therapeutics Stockholders Approve Amended 2022 Equity Incentive Plan and Elect New Directors – June 2026 - Minichart
Acrivon Therapeutics shareholders approve equity plan changes and director elections - Investing.com UK
Acrivon Therapeutics shareholders approve equity plan changes and director elections By Investing.com - Investing.com India
Acrivon amends equity plan, shareholders approve 3,000,000-share increase - TradingView
Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directors - Stock Titan
Acrivon Therapeutics Inc (ACRV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acrivon Therapeutics Inc (ACRV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acrivon Therapeutics Inc (ACRV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acrivon Therapeutics Inc (ACRV) Institutional Confidence - TradingKey
Acrivon Therapeutics Inc (ACRV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acrivon Therapeutics Inc (ACRV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acrivon Therapeutics Inc (ACRV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gabelli Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8 - Moomoo
Oppenheimer Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8 - Moomoo
Acrivon Therapeutics (ACRV) Shows Modest Upside Amidst Key Technical LevelsDealer Delta - newsline.com
Acrivon Therapeutics (ACRV) Faces Continued Pressure, Testing Key Support After 7.7% DeclinePercent Above MA - newsline.com
Acrivon Therapeutics (ACRV) Slides 7.7% as Support Test Looms After Bearish MomentumDealer Positioning - newsline.com
ACRV Q1 2026 Earnings: EPS Beats Estimates as Clinical Pipeline AdvancesEPS Estimate Trend - newsline.com
ACRV Q1 2026 Earnings: Positive EPS Surprise Amid Pre-Revenue Pipeline ProgressEarnings Acceleration Picks - newsline.com
Acrivon Therapeutics (ACRV) Slides 1.23% as Stock Tests Key Support at $1.53Pairs Trade - The Legal Advocate
Acrivon Therapeutics Q1 2026 Earnings: Narrower Loss Per Share as Pipeline Progress ContinuesSurprise Factor Analysis - The Legal Advocate
Acrivon Therapeutics (ACRV) Edges Higher: Biotech Stock Tests Key Resistance at $1.77Double EMA - newsline.com
Acrivon (ACRV) CEO and EVP report RSU-related tax withholding move - Stock Titan
Acrivon Therapeutics (ACRV) Slides 1.71% as Stock Nears Critical Support ZoneDollar Neutral Pair - The Legal Advocate
Acrivon Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineDividend Increase Stocks - newsline.com
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline By Investing.com - Investing.com Australia
Acrivon Therapeutics CEO to Participate in Virtual Fireside Chat at TD Cowen’s 7th Annual Oncology Innovation Summit - Quiver Quantitative
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - The Manila Times
1.88%
2.71%
자본화:
|
볼륨(24시간):